Axitinib and low-dose etoposide for relapsed brain tumors in children
Part of Cancer clinical trials.
This trial tests a combination of two oral drugs (axitinib and metronomic etoposide) for children and young adults whose medulloblastoma or ependymoma has come back or is not responding to standard therapy. The goal is to see if this daily pill treatment can control tumor growth with manageable side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of brain tumor called medulloblastoma or ependymoma.
- The tumor has come back or is not responding to standard treatments.
- You are between 4 and 25 years old and weigh more than 44 pounds (20 kg).
- You can swallow pills (capsules) and are overall well enough to go about daily activities (Karnofsky or Lansky score of 70% or higher).
- Your blood counts, heart, kidney, and liver function are within safe limits (checked by tests).
- If you are of childbearing age, you agree to use effective contraception and must have a negative pregnancy test before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a combination treatment (ibrutinib plus indoximod along with chemotherapy) for children with brain tumors that have come back or are hard to treat. It may help shrink active tumor or control the disease when standard treatments can’t cure it.
This study tests a personalized treatment plan for children and young adults whose medulloblastoma or ependymoma has come back. It aims to guide doctors using new tissue from surgery or biopsy after earlier treatments are fully finished.
This Phase 2 trial tests how doctors choose treatment for infants and young children with newly diagnosed medulloblastoma, based on MRI/CSF staging and lab testing of the tumor. It may help by matching therapy intensity to the child’s specific risk level and tumor type.
This trial tests a new immune therapy using your child's own specially trained white blood cells to fight brain tumors. The treatment is given directly into the fluid around the brain, and it is for children with specific types of brain cancer.
This trial studies how brain tumors (like high-risk gliomas, medulloblastoma, and ependymoma) respond to treatment and why they sometimes become resistant. It is for young people aged 15 to 39 and aims to use tumor tissue samples to understand the tumor better and guide future therapies.
This trial tests a treatment that targets tumor blood-vessel growth to slow or shrink relapsed/progressive brain tumors in children. It may help if standard options are no longer working.
Hear when a new Medulloblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.